Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
European Journal of Nuclear Medicine and Molecular Imaging · 2023
DOI: 10.1007/s00259-023-06247-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Narjess Ayati und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Melanoma, Metabolic Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Paracelsus Medical University.
Abstract (Originalsprache)
Purpose
Immune checkpoint inhibitors (ICIs) are widely used in metastatic melanoma and dramatically alter the treatment of these patients. Given the high cost and potential toxicity, a reliable method for evaluating treatment response is needed. In this study, we assessed tumor response in patients with metastatic melanoma treated with ICIs using three modified response criteria: PET Response Evaluation Criteria for Immunotherapy (PERCIMT), PET Response Criteria in Solid Tumors for up to Five Lesions (PERCIST5), and immunotherapy-modified PET Response Criteria in Solid Tumors for up to Five Lesions (imPERCIST5).
Methods
Ninety-one patients with non-resectable stage IV metastatic melanoma who received ICIs were retrospectively enrolled in this study. Each patient had two [ 18 F]FDG PET/CT scans performed before and after ICI therapy. Responses at the follow-up scan were evaluated according to PERCIMT, PERCIST5, and imPERCIST5 criteria. Patients were classified into four groups: complete metabolic response (CMR), partial metabolic response (PMR), progressive metabolic disease (PMD), and stable metabolic disease (SMD). To assess the “disease control rate,” two groups have been defined based on each criterion: patients with CMR, PMR, and SMD as “disease-controlled group (i.e., responders)” and PMD as the “uncontrolled-disease group (i.e., non-responders)”. The correspondence between metabolic tumor response defined by these criteria and clinical outcome was assessed and compared.
Results
The response and the disease control rates were 40.7% and 71.4%, 41.8% and 50.5%, and 54.9% and 74.7% based on the PERCIMT, PERCIST5, and imPERCIST5 criteria, respectively. PERCIMT and imPERCIST5 showed significantly different disease control rates from that of PERCIST5 ( P < 0.001), whereas it was not significant between PERCIMT and imPERCIST5. Overall survival was significantly longer in the metabolic responder groups than in the non-responder groups based on PERCIMT and PERCIST5 criteria (PERCIMT: 2.48 versus 1.47 years, P = 0.003; PERCIST5: 2.57 versus 1.81 years. P = 0.017). However, according to imPERCIST5 criterion, this difference was not observed ( P = 0.12).
Conclusion
Although the appearance of new lesions can be secondary to an inflammatory response to ICIs and indicative of pseudoprogression, given the higher rate of true progression, the appearance of new lesions should be interpreted deliberately. Of the three assessed modified criteria, PERCIMT appear to provide more reliable metabolic response assessment that correlates strongly with overall patient survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Muellner Hauptstrasse 48, 5020, Salzburg, Austria.
- Department of Nuclear Medicine, Shahid Rajaie Cardiovascular, Medical & Research Center, Tehran, Iran.
- Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
- Biostatistics and Publication of Clinical Trial Studies, Research and Innovation Management (RIM), Paracelsus Medical University, Salzburg, Austria.
- Department of Ophthalmology and Optometry, Paracelsus Medical University, Salzburg, Austria.
Förderung
- Paracelsus Medical University
Zitieren
APA
Ayati, N., Jamshidi-Araghi, Z., Hoellwerth, M., Schweighofer-Zwink, G., Hitzl, W., Koelblinger, P., Pirich, C., & Beheshti, M. (2023). Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06247-8
Vancouver
Ayati N, Jamshidi-Araghi Z, Hoellwerth M, Schweighofer-Zwink G, Hitzl W, Koelblinger P, et al. Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06247-8
BibTeX
@article{Ayati2023,
author = {Ayati, Narjess and Jamshidi-Araghi, Zahra and Hoellwerth, Magdalena and Schweighofer-Zwink, Gregor and Hitzl, Wolfgang and Koelblinger, Peter and Pirich, Christian and Beheshti, Mohsen},
title = {Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2023},
doi = {10.1007/s00259-023-06247-8}
}
EUVIMED